Project Grant R01AI185073
Award Date
8/15/24
Completion Date
7/31/29
Dollars Obligated
$559K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
This federal Project Grant award, valued at $685,980.00 and issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to isolate broadly protective monoclonal antibodies for Crimean-Congo Hemorrhagic Fever (CCHF). The primary objectives are to: 1) Develop a cohort of CCHF survivors and isolate a panel of monoclonal antibodies against the CCHF virus envelope; 2) Test the efficacy of the...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $13,946,446 Cooperative Agreement titled "PROVIDENT: PREPOSITIONING OPTIMIZED STRATEGIES FOR VACCINES AND IMMUNOTHERAPEUTICS AGAINST DIVERSE EMERGING INFECTIOUS THREATS" to the Albert Einstein College of Medicine. The overarching goal of this 5-year project is to deliver "plug-and-play" vaccine and therapeutic antibody...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $244,440.00 to the Albert Einstein College of Medicine to conduct research on how Ly6C+ monocytes respond to and help clear microbial pathogen infections. The research aims to define the chemotactic cues, receptors, and mechanisms involved in how these monocytes home to infection sites and form stable clusters to deliver local...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $355,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Georgia Southern University Research & Service Foundation Inc. The grant will support research to develop comprehensive morphological and molecular identification tools for Hyalomma tick species that are vectors of Crimean-Congo Hemorrhagic Fever virus. The project aims to resolve the systematics of closely related...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $244,440 to Albert Einstein College of Medicine to conduct research exploring the role of cytolytic ZEB2+ memory CD4+ T cells in providing protection against the liver stage of malaria infection. The goal is to gain insights into the cellular immune determinants associated with natural clinical immunity to malaria, which could inform...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $843,620 to the Albert Einstein College of Medicine to develop broadly inhibitory antibody therapies against arthritogenic and encephalitic alphaviruses. The research aims to: 1) engineer Fc mutations into broadly protective antibodies to enhance their in vitro and in vivo properties, 2) perform viral escape studies to...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Albert Einstein College of Medicine in Bronx, NY. The $1,486,800 award, with a project period from November 7, 2024 to October 31, 2029, supports research on the role of TNFRSF14 signaling in promoting antibody-dependent cell-mediated cytotoxicity (ADCC) as a potential strategy for herpes simplex virus (HSV) vaccine development. The...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $318,085.00 to conduct research on the role of cell, antigen, and antibody in controlling virus infection through Fc-dependent mechanisms. The key focus is on understanding how to optimize antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and...
This federal Project Grant award, totaling $820,246.00 and awarded on May 22, 2025 by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research), supports research to identify and characterize the secreted proteins from the Mycobacterium tuberculosis ESX5 transport system. The research aims to determine the role of these secreted proteins in tuberculosis (TB) disease pathogenesis and understand the immunological basis for why an ESX5 mutant...
This $510,306 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to advance the understanding of virus-host interactions for developing a cure against chronic hepatitis B virus (HBV) infections. The primary goal is to investigate the mechanisms by which interferon-alpha treatment can lead to a functional cure for HBV, as well as explore the impact of HBV...